MLN9708

Cat. # SI9715

Background: MLN9708 is a proteasome inhibitor.[1] MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Much like Bortezomib, the active form of MLN9708 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively.[2]

Application: *In vitro* and cellular studies of proteasome function.

Product Information:

CAS No.	1201902-80-8
Purity:	>99.6% by HPLC
Molecular Weight:	517.12 Da
Physical State:	Powder
Quantity:	5mg
Solubility:	DMSO (103 mg/mL); ethanol (<1 mg/mL); water (<1 mg/mL)
Storage:	Store desiccated as supplied at -20ºC for 2 years.



Formula: $C_{20}H_{23}BCl_2N_2O_9$

References

1. Kupperman, E., Lee, E.C. et al. (2010). "Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer." Cancer Res **70**(5): 1970-1980.

2. Schrader, J., Hennenberg, F., et al. (2016). "The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design." Science **353**(6299): 594-598

All products are for research use only • Not intended for human or animal diagnostic or therapeutic uses
Copyright © 2011 LifeSensors, Inc. All Rights Reserved